Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
830000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the 12th Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) issued through a third-party allotment
Who receives how much830,000Shares
Number of shares issued during the month: 830,000 shares (new shares)
EVO FUND (issued on 8 December 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
830,000 shares issued during the month / 7,624,419 shares outstanding at the end of the previous month (approximately 10.9%)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise prices during the month: ¥171, ¥258, ¥277, ¥287, ¥300, ¥400 and ¥377. Details and floor of the adjustment clause: Not disclosed
Number of Stock Acquisition Rights
Total issued: 60,000; unexercised at the end of the previous month: 52,200; unexercised at the end of the target month: 43,900
Most recent equity financing
Issued on 8 December 2025: new shares through a third-party allotment, the 12th Stock Acquisition Rights (with an exercise price adjustment clause), the 13th Stock Acquisition Rights, and the 1st unsecured straight bonds (private placement to a small number of investors). Amount: Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the 12th Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) issued through a third-party allotment |
| Number of shares to be issued or disposed of | Number of shares issued during the month: 830,000 shares (new shares) |
| Intended allottee | EVO FUND (issued on 8 December 2025) |
| Dilution Rate | 830,000 shares issued during the month / 7,624,419 shares outstanding at the end of the previous month (approximately 10.9%) |
| Total number of issued shares | 7,624,419 shares (as of the end of the month preceding the target month) → Not disclosed |
| Exercise price | Exercise prices during the month: ¥171, ¥258, ¥277, ¥287, ¥300, ¥400 and ¥377. Details and floor of the adjustment clause: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 60,000; unexercised at the end of the previous month: 52,200; unexercised at the end of the target month: 43,900 |
| Most recent equity financing | Issued on 8 December 2025: new shares through a third-party allotment, the 12th Stock Acquisition Rights (with an exercise price adjustment clause), the 13th Stock Acquisition Rights, and the 1st unsecured straight bonds (private placement to a small number of investors). Amount: Not disclosed |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the 12th Stock Acquisition Rights in April 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.